Dr. Byrd Discusses the Future Treatment of CLL

John C. Byrd, MD
Published: Friday, Mar 23, 2018



John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Byrd says that he is very excited to see the results of current clinical trials investigating triplet therapies in CLL. Additionally, he says that using targeted therapy early in patients who are determined to be high risk can subvert the clonal evolution in patients developing the disease is another exciting area of investigation.

An area of unmet need in CLL is the treatment of patients with Richter’s transformation. There are no effective therapies as of now, says Byrd, so efforts must be put toward developing agents for that subgroup of patients.


John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Byrd says that he is very excited to see the results of current clinical trials investigating triplet therapies in CLL. Additionally, he says that using targeted therapy early in patients who are determined to be high risk can subvert the clonal evolution in patients developing the disease is another exciting area of investigation.

An area of unmet need in CLL is the treatment of patients with Richter’s transformation. There are no effective therapies as of now, says Byrd, so efforts must be put toward developing agents for that subgroup of patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x